1. Impact of circulating biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II study. (December 2016) Authors: Tijeras-Raballand, A.; De Gramont, A.; Chiron, M.; Bachet, J.B.; André, T.; Auby, D.; Desramé, J.; Baba-Ahmed, N.; Lecaille, C.; Lebrun, V.; Louvet, C.; Tournigand, C.; Benner, S.; Attia, M.; De Gramont, A.; Bonnetain, F.; Chibaudel, B. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Predictive biomarkers of response to the tubulin-binding agent DM4 in colorectal cancer preclinical models. (December 2016) Authors: El-Murr, N.; Nicolazzi, C.; Calvet, L.; Blot, L.; Lefebvre, A.M.; Theilhaber, J.; Zilocchi, C.; Demers, B.; Blanc, V.; Combeau, C.; Sidhu, S.S.; Chiron, M.; Henry, C. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗